WHEN THE DRUG MARKET CHANGES FASTER THAN OUR KNOWLEDGE

We can have accurate information and still reach the wrong assessment.
In the drug landscape, this matters.
Not because the information is inaccurate, but because it may be accurate about what was true before, while the environment has already changed.
We may know the substance, its effects, how it has appeared before, and how it was previously distributed.
But what if:
• Is the form different?
• Has the composition changed?
• Does it appear in a new combination?
• Has the method of distribution changed?
• Is something that was unusual yesterday starting to appear repeatedly today?
Then the question is not only what we know.
The question is whether what we know still fully describes the situation.
This is where, in my view, we need to change the way we read change itself.
When something new is observed, instead of immediately placing it into a familiar category, we can first ask a series of analytical questions:
• What exactly is different?
Not simply what was found, but what is different from what we previously knew.
• Where did the change appear?
Location, timing, and circumstances can sometimes be just as important as the substance itself.
• What could it be connected to?
One piece of information may not carry enough weight on its own. But when it appears alongside another change, it may raise a question that had not been asked before.
• What could it mean if this continues?
Not as a prediction and not as a conclusion, but as an assessment of possible consequences.
• Who needs to have this information?
Because information that remains isolated may have limited value. When it reaches a professional or service that can place it into a broader context, its significance can change.
This does not mean that every change is a threat. Nor does every unusual occurrence need to be immediately declared a trend.
Quite the opposite.
It takes discipline to distinguish a new signal from an isolated occurrence, and a possible risk from an established fact.
But it also takes discipline not to wait until a change becomes an obvious problem before asking what has happened.
Imagine different professionals, each observing one part of the same emerging change:
• One notices something unexpected in a laboratory.
• Another observes a different reaction in a patient.
• Someone else notices a substance appearing in a new context.
• Another professional identifies a change in the way it is being distributed.
None of these observations, on its own, necessarily explains the whole picture.
But when relevant information is connected, we can gain something more valuable than an isolated data point: context.
And this is where I see the value of coordination.
Not everyone needs to know the entire picture, but every relevant observation should have a path to the person or service capable of connecting it with other information.
That is why it is not enough simply to collect data.
We also need to recognize when two seemingly separate changes may deserve to be considered together.
It is not enough to respond only to what has already been confirmed.
We need to leave room for a professional question:
What is this change telling us?
For me, this is one of the practical directions of Early Risk Intelligence.
Not an assumption.
Not labeling.
Not creating fear.
But carefully observing change, placing it in context, connecting relevant information, and thoughtfully assessing what may follow.
So perhaps we should not ask only:
What do we know about this?
We should also ask:
What is different from the last time we looked at it?
Because in an environment that is changing, even the most accurate information can become insufficient if we stop questioning it against the new reality.
Sometimes the most important information is not the information that tells us what is happening. It is the information that tells us something has started to change.